Janus will close its popular
Global Life Sciences,
Olympus funds to new investors at the close of business today. Applications postmarked today will still be accepted.
After that, only current shareholders and retirement plan investors will be able to invest in Global Life Sciences and Worldwide. The door to Olympus is slightly more ajar. Financial advisers who already have clients in the fund can open new accounts for their clients, and the fund can still be added to new retirement plans.
"The managers are the ones who decide when to close their fund. They know when its size requires closing to best serve current shareholders," says Jane Ingalls, a Janus spokesperson.
The closings leave the $290 billion growth fund titan with seven closed funds out of a lineup of 15 equity funds. Also closed are
Global Technology, and
Venture. The firm plans to launch a Twenty-like growth fund,
, in June, and investors have
Strategic Value, which launched in March and already has more than $2 billion in assets.
With so many popular funds now off-limits to new investors, Janus is left with a diminished product lineup even as money continues to pour in at an unprecedented rate. In the first quarter Janus took in more than $28 billion, more than four times runner-up
The three funds that are about to close are among the top-15 sellers this year through March 31, according to the latest figures from Boston fund consultant
. Like most Janus funds, each has followed an aggressive growth strategy to eye-catching returns. The average stock fund has about $1 billion in assets, according to
. Each of these funds took in $2 billion or more in this year's first quarter.
The $8 billion, large-cap growth Olympus fund has ridden tech stocks to a 53.9% annualized return over the past three years, beating 99% of its peers, according to Morningstar. The fund, which took in more than $2 billion in the first quarter of this year, has more than 75% of its assets invested in tech and telecom stocks.
The $3 billion Global Life Sciences fund, which invests in the health care sector, is up 68.9% over the past year, beating more than 70% of its peers. It took in more than $3 billion in the first quarter.
The $42 billion Worldwide fund, co-managed by high-profile international specialist Helen Young Hayes, has returned more than 30% annually, on average, over the past five years, beating 99% of its global fund peers. It is one of the 25 largest mutual funds and took in more than $6 billion in the first quarter.
As you might imagine, the recent selloff in technology stocks has slowed these funds a bit. Olympus is down 3.6% since Jan. 1, trailing 93% of its peers, according to Morningstar. Global Life Sciences is up 10.1%, but that trails 88% of its peers. Worldwide has held up best on a relative basis. Its 1.3% year-to-date return beats 93% of its peers.